Marcaina

Bupivacaine Hydrochloride, the active ingredient in Marcaina, is a local anesthetic presented as a solution for epidural and infiltration use. It provides surgical anesthesia, pain management, and epidural analgesia in adult patients undergoing various procedures.

GNH USA supplies Marcaina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Bupivacaine is a local anesthetic used in clinical situations that require nerve block or analgesia.

Surgical anesthesia: delivers dense anesthesia for operative procedures. Pain management: offers postoperative pain control. Epidural analgesia: provides continuous analgesia during labor or postoperative periods.

Bupivacaine may cause a range of adverse reactions, most of which are dose‑dependent and related to its local anesthetic properties.

Common Side Effects: - Transient numbness or tingling at the injection site. - Mild hypotension due to sympathetic blockade. - Headache, especially after epidural administration. - Nausea or vomiting. - Metallic taste. - Localized muscle weakness.

Serious or Rare Side Effects: - Cardiovascular toxicity such as arrhythmias or cardiac arrest. - Central nervous system toxicity including seizures or loss of consciousness. - Allergic reactions ranging from rash to anaphylaxis. - Persistent neurologic deficits if administered intrathecally in error.

When using Marcaina, clinicians should observe standard safety measures for local anesthetics.

Allergy assessment: verify no known hypersensitivity to amide‑type anesthetics. Cardiovascular monitoring: observe heart rate and blood pressure during and after administration. Dose limitation: avoid exceeding recommended maximum doses for the chosen route. Elderly or compromised patients: adjust technique and monitor closely for systemic toxicity. Pregnancy and lactation: use only if benefit outweighs potential risk, as data are limited. Store at below 25°C: keep in original container, protect from moisture and light.

Bupivacaine can interact with other agents that affect cardiac conduction or central nervous system function.

Major Interactions (Avoid): - Class I antiarrhythmic drugs (e.g., quinidine, procainamide). - Other potent local anesthetics administered concurrently. - Beta‑adrenergic blockers that may exacerbate bradycardia.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (may enhance hypotensive effects). - CNS depressants such as benzodiazepines or opioids (increase risk of respiratory depression). - MAO inhibitors (potential for prolonged anesthetic effect).